Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm
| Brand name | CARVEDILOL |
| Generic name | CARVEDILOL |
| Active ingredient(s) | CARVEDILOL |
| Distributed by / for | Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 47430 |
| NDC | 68462-165-05 |
| Full product label | Carvedilol Tablets, USP, 25 mg, 500 Tablets per carton, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Plot No. 2, Phase-2, Pharma Zone SEZ, Pithampur, Dist.-Dhar, Madhya Pradesh 454 775, India. Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 47430 NDC: 68462-165-05 |
| Recalling firm | Glenmark Pharmaceuticals Inc., USA |
| Distribution | Nationwide within the USA |
| Quantity | 14,976 bottles |
| Recall initiated | 2025-08-06 |
| Report date | 2025-08-20 |
| Recall completed | — |
| Recall number | D-0588-2025 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Mahwah NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗